Celebrating its 10th Anniversary

the Alzheimer's Drug Discovery Foundation presents

 

THE 10th INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY

September 14-15, 2009   Jersey City, NJ, USA (across from NYC on the Hudson)

 

  HOME

  PROGRAM

  SPEAKERS

  SCHOLARSHIPS

  REGISTRATION

  VENUE/ACCOMMODATIONS

  SPONSORSHIP/EXHIBIT

  SUPPORTERS

  CONTACT

ABOUT THIS MEETING

 

The 10th International Conference on Alzheimer's Disease Drug Discovery was presented by the Alzheimer's Drug Discovery Foundation (ADDF), the only public charity solely dedicated to rapidly accelerating the discovery and development of drugs to prevent, treat and cure Alzheimer's disease and cognitive aging.  This conference brought together academic and industry scientists to accelerate the development of novel drug discovery programs for Alzheimer’s disease and related dementias.

 

OBJECTIVES

 

· To discuss scientific progress on drug discovery programs aimed at treating Alzheimer’s disease and related dementias.

· To increase networking opportunities for scientists to share information and resources.

· To publish and distribute a post-meeting report in a peer-reviewed scientific journal.

 

SESSIONS AND CHAIRS

 

I. Neuroprotection & Prevention

Chair: Frank Longo, MD, PhD, Stanford University

 

 

II. Anti-Amyloid & Protein Misfolding

Chair: Michael Wolfe, PhD, Brigham and Women's Hospital

 

 

III. Anti-Tangles & Frontotemporal Dementia

Chair: Jeff Kuret, PhD, Ohio State University

 

 

IV. Alternative Strategies: New Targets for ALZHEIMER'S DISEASE Therapy

Chair: Diana Shineman, PhD, Alzheimer’s Drug Discovery Foundation

 

 

Plenary Talk: Bridging Neurocognitive Aging and Disease Modification: Targeting Functional Mechanisms of Impairment

Michela Gallagher, PhD, Johns Hopkins University

 

 

Plenary Talk: TDP-43 as a New Target for Neurodegenerative Disease

Virginia Lee, PhD, MBA, University of Pennsylvania

 

 

EVENT PICTURES

 

EVENT SUMMARY

 

Click below to read the conference summary authored by Dr. Diana Shineman, ADDF's Director of Scientific Affairs. 

 

TARGET AUDIENCE

 

The 2009 edition of this conference attracted attendees from around the globe.  Attendees included:

 

- Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases or CNS

- Business development and licensing professionals

- Alliance management professionals

- Venture capitalists and other investors.

 

9th EDITION (OCT. 2008)

 

Review program, speakers, supporters of the 9th International Conference on Alzheimer's Drug Discovery held last year in New York City.

 

 

SPONSORS

 

OUR  SPONSORS:


 

 

 

 


 

  

 

         

 

 

 

 

 

  © 2009 WEF